Does health insurance cover Ozempic, Mounjaro or Wegovy in India?
What IRDAI's rules and real policy wordings say about GLP‑1 medicines, OPD add-ons, diabetes plans, employer cover and weight-loss surgery.
Written for India. Reading from the US? US versionComing soon
Usually not. Most Indian health policies pay for hospital stays and exclude outpatient treatment, which is how these weekly medicines are used. OPD add-ons and diabetes plans have small yearly limits, and some exclude medicines entirely. Some employer policies can add outpatient pharmacy cover. We found no IRDAI rule requiring insurers to pay.
Key takeaways
- Most Indian health policies don't pay for Ozempic, Mounjaro or Wegovy bought each month, because they list "treatment taken on outpatient basis" as an exclusion.1,2
- Excl06, the obesity exclusion IRDAI standardised in 2019 and withdrew in 2024, covered weight-loss surgery only; several policies we checked still print it.3,16,23
- Star Health's Diabetes Safe caps yearly outpatient cover per person at ₹1,000–5,500 on Plan A and from ₹500 on Plan B, at network facilities only.4
- Employer (group) health policies can buy an extension that adds outpatient cover, which one insurer's wording defines as including pharmacy, up to a set limit.6
- Since 24 July 2026, the CGHS scheme allows injectable semaglutide and tirzepatide only at a BMI of 35 or more, or 32.5 or more with a listed condition.7
- GLP‑1 medicines are prescription-only in India, not sold over the counter.8
- A government statement on 1 Apr 2026 said only endocrinologists, internal-medicine specialists and cardiologists can prescribe them.8 CDSCO expert-committee minutes attach a similar condition to some approvals (endocrinologist or internal-medicine specialist), but we found no rule covering every brand.9,10
- The risks are the same whoever pays: Guide 5. Guide 6 lists the July 2026 generic recalls.
- We name insurers only to quote their policy wording. Nothing here recommends an insurer, a plan or a brand.
On this page
- Why don't most health policies pay for Ozempic, Mounjaro or Wegovy?
- What did IRDAI's standard obesity exclusion say?
- Can an OPD or wellness add-on pay for GLP-1 medicines?
- Do diabetes insurance plans cover Ozempic or Mounjaro?
- Does my employer's health insurance cover it?
- How is bariatric surgery cover different?
- What about CGHS and Ayushman Bharat?
- How do I check my own policy?
- Questions people ask
- How we researched this
Why don't most health policies pay for Ozempic, Mounjaro or Wegovy?
Most Indian health policies pay for hospital stays. Weekly injections bought at a pharmacy are outpatient treatment, which most base policies exclude in writing.1,2
HDFC ERGO's my: Optima Secure wording is a typical example. Its list of exclusions has one plain line: "Treatment taken on outpatient basis."1 The same insurer's diabetes plan, Energy, carries the same exclusion.2
GLP‑1 medicines such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are injected under the skin once a week.24,25 That is the US labels' wording; we found no Indian label online. There is no hospital stay for a base policy to pay against.
BusinessToday reported in March 2026 that IRDAI data shows "metabolic and obesity-related therapies are largely excluded from retail health insurance policies".12 Novo Nordisk's India head told the paper he hoped obesity treatment "gets coverage", but that "we may have to wait".12 An earlier BusinessToday report said limited cover keeps treatment "largely out-of-pocket for most patients".13
We found no IRDAI circular or statement on GLP‑1 medicines, either requiring cover or ruling it out. That leaves your own policy wording to settle it.
For scale, Ozempic's MRP is ₹5,660–9,100 for 4 weekly doses, and Wegovy's is ₹5,660–16,400, the top price being the 2.4 mg pen.5,26 A year at 2.4 mg is 13 × ₹16,400 = ₹2,13,200. One maker's generic semaglutide pen starts at ₹1,800 for 4 doses.11 Mounjaro's MRP is in our short answer What is the MRP of Mounjaro in India? What a year on a GLP‑1 costs, all in adds the doctor visits and tests. How prices fell is in What changed when semaglutide's patent expired.
What did IRDAI's standard obesity exclusion say?
The obesity exclusion IRDAI standardised in 2019, code Excl06, was about weight-loss surgery. It said nothing about medicines such as Ozempic, Mounjaro or Wegovy.3
IRDAI (the Insurance Regulatory and Development Authority of India) set standard wording for common exclusions in 2019.3 An insurer that used one of these exclusions had to copy the wording "in-verbatim", in individual and group policies alike.3
In 2020 that rule moved into IRDAI's master circular on standard health products.23 IRDAI's health master circular of 29 May 2024 lists that 2020 circular as superseded.16
Obesity/ Weight Control: Code-Excl06. "Expenses related to the surgical treatment of obesity that does not fulfil all the below conditions: 1) Surgery to be conducted is upon the advice of the Doctor 2) The surgery/Procedure conducted should be supported by clinical protocols 3) The member has to be 18 years of age or older and 4) Body Mass Index (BMI); a) greater than or equal to 40 or b) greater than or equal to 35 in conjunction with any of the following severe co-morbidities following failure of less invasive methods of weight loss: i. Obesity-related cardiomyopathy ii. Coronary heart disease iii. Severe Sleep Apnea iv. Uncontrolled Type2 Diabetes"
IRDAI, Guidelines on Standardization of Exclusions, 27 Sep 2019, since withdrawn3
Some current policies still print it word for word. We found it in HDFC ERGO's my: Optima Secure, Niva Bupa's ReAssure 2.0 and SBI General's Super Health.1,14,15
In these policies, the outpatient exclusion is what keeps GLP‑1 medicines out.1
We found no standard exclusion wording in the 2024 circular. It asks insurers to give every policyholder a customer information sheet with a "summary of exclusions which policy does not cover".19 Each new product or add-on is approved by the insurer's own product management committee.19 So your policy's own wording decides what is excluded.
SBI General's wording defines obesity by the WHO cut-off, a BMI of 30 or more.15 The 2009 Indian consensus puts obesity at a BMI of 25 or more for Indians.17 Guide 1 explains the Indian numbers.
Can an OPD or wellness add-on pay for GLP-1 medicines?
Sometimes, within a small yearly limit. Some outpatient add-ons pay for consultations only and exclude every medicine, so the wording matters more than the name.18
IRDAI requires insurers to make products or add-ons available for outpatient (OPD) treatment.19 It adds that this does not mean any one product must cover everything.19
HDFC ERGO's Optima Wellbeing add-on shows how narrow "outpatient" can be. It offers doctor consultations and unlimited diet and nutrition e-consultations.18 But its terms say: "All Drugs or treatments are excluded under this Add-on."18 Medicines get only a discount of up to 20% on home delivery from the insurer's partner network.18
Other outpatient covers do pay for medicines, up to a yearly cap. The diabetes plan in the next section is one.4 When you read any OPD add-on, look for these:
- Medicines named as covered, not just consultations and tests.
- The yearly limit in rupees, per person or per family.
- One shared limit: whether consultations, tests and medicines all come out of the same amount.
- Cashless or refund: whether you must buy through the insurer's network.
Do diabetes insurance plans cover Ozempic or Mounjaro?
Diabetes plans cover diabetes from early on, but mostly in hospital. Where one pays outpatient costs, its yearly limit can be less than a month's medicine.2,4,5
HDFC ERGO's Energy is for people with diabetes (type 1 or 2), high blood pressure or prediabetes.2 Prediabetes means blood sugar raised, but below the diabetes range. Problems linked to diabetes are not held back by its waiting period for existing illness.2 It refunds up to ₹750 for an HbA1c test, twice a year, but still excludes "Treatment taken on Outpatient basis".2
Star Health's Diabetes Safe has a separate outpatient section, paid only at its network facilities.4 It pays for "medical consultation, other diagnostics, medicines and drugs" up to a yearly limit.4 That limit comes out of the sum insured.4 Fasting, after-meal and HbA1c tests have their own cap of ₹1,500 a year.4
| Sum insured | Plan A, yearly outpatient limit | Plan B, yearly outpatient limit |
|---|---|---|
| ₹3 lakh | ₹1,000 | ₹500 |
| ₹4 lakh | ₹2,500 | ₹2,000 |
| ₹5 lakh | ₹3,500 | ₹3,000 |
| ₹10 lakh | ₹5,500 | ₹5,000 |
Star Health Diabetes Safe, individual cover, from the policy wording filed with IRDAI (version 12, 2021).4 Star Health's website blocked our checks, so we could not open a newer version. Not a recommendation.
A worked example. Take the ₹5 lakh Plan A, with an outpatient limit of ₹3,500 a year.4 Ozempic's starting dose costs ₹5,660 for 4 weekly doses.5 So the whole year's limit covers less than one month, before any consultation or test is claimed from it.
A hospital stay opens one more route. my: Optima Secure pays costs for up to 180 days after discharge.1 They must be for the same condition that needed the admission.1 We found no published claim decision on whether a GLP‑1 started at discharge counts.
If you have type 2 diabetes, the diabetes path puts these medicines next to metformin and insulin. HbA1c explained covers the test these plans pay for.
Medicine MRP, doctor visits and tests over 6 and 12 months, by dose step. No sign-up.
Does my employer's health insurance cover it?
It depends on what your employer bought. Group policies can add outpatient cover, which may include pharmacy, and can even delete the obesity exclusion, for an extra premium.6
Universal Sompo's group policy shows the options. Its base wording excludes "Any expenses incurred on OPD treatment."6 An extension deletes that exclusion and pays for outpatient visits, up to a limit in the policy schedule.6 Its wording defines outpatient as a visit to a clinic or hospital "for diagnosis (including Pharmacy)".6
A second extension deletes Excl06, so weight-loss surgery is paid up to a set limit.6 That one is about surgery, not medicines.6
The IRDAI data BusinessToday reported was about retail policies, the ones people buy for themselves.12 We found no public data on how many employer policies pay for GLP‑1 medicines. Questions worth putting to HR:
- Does our policy include OPD cover, and does it include pharmacy?
- What is the yearly OPD limit, and is it per person or per family?
- Are any medicines or conditions excluded from OPD?
- Can I see the policy wording and the schedule?
If you're paying for a parent or partner, the family-member path covers how to talk about it and who pays.
How is bariatric surgery cover different?
Weight-loss (bariatric) surgery is a hospital stay, so many policies can pay. Policies that use the Excl06 wording set the bar at a BMI of 40, or 35 with listed conditions.3
In a policy that uses this wording, surgery that meets every condition is not excluded.3 A sublimit can still cap payment, as in SBI General's wording below.15 The conditions are a doctor's advice, clinical protocols, age 18 or over, and the BMI rule.3
Some policies name the surgery as a benefit. SBI General's Super Health has a "Bariatric Surgery Cover" with the same BMI rule.15 It caps payment at a sublimit, excludes surgery "for Cosmetic reasons" and needs two surgeons to agree it's appropriate.15
The insurers' bar is higher than surgeons' own advice for Asians. Asia-Pacific surgeons (IFSO-APC) say surgery should be considered for Asians at a BMI of 35.20 With poorly controlled type 2 diabetes, they say 30.20 India's surgeons' society, OSSI, follows those criteria.21
Each rule uses a different number. The 2009 Indian consensus puts obesity at a BMI of 25.17 CGHS allows GLP‑1 injections from 35, or 32.5 with a listed condition.7 Policies using Excl06 cover surgery from 40, or 35 with listed conditions.3
For a person 165 cm (5 ft 5 in) tall, those are about 68 kg, 95 kg (88 kg) and 109 kg (95 kg). BMI is weight in kg divided by height in metres, squared. None of these numbers says a treatment is right for you. Work out your own with the BMI and waist tool.
Guide 3 compares surgery with medicines and other options. Our posts Bariatric surgery vs GLP‑1 medicines and How much does bariatric surgery cost in India? go deeper.
What about CGHS and Ayushman Bharat?
Since 24 July 2026, the Central Government Health Scheme (CGHS) allows injectable semaglutide and tirzepatide only under strict rules. Ayushman Bharat PM-JAY pays for hospital care.7,22
A Health Ministry memo of 24 July 2026 added Mounjaro (tirzepatide) to the CGHS list of restricted drugs.7 Both it and injectable semaglutide may now be prescribed under CGHS only by these rules:7
- BMI: 35 or more, or 32.5 or more with a listed condition.7 The conditions are type 2 diabetes uncontrolled despite metformin and two other tablets, severe sleep apnoea, heart or artery disease, fatty liver disease (MASLD) and chronic kidney disease.7
- First: at least three months of lifestyle change, diet counselling and supervised exercise.7
- Who prescribes: an endocrinologist or internal-medicine specialist at a government hospital.7 The head of department endorses it, for six months at a time.7
- Not with: past pancreatitis, pregnancy or breastfeeding, among others.7 Nor with a personal or family history of MTC (a rare thyroid cancer), or MEN2 (an inherited gland condition).7
- Checks: monthly for the first three months, then every three months.7
These are the scheme's rules for paying for the medicine. A doctor still decides whether it suits each person.
PM-JAY gives each entitled family ₹5 lakh a year for hospital care.22 It covers 3 days before and 15 days after a stay, including medicines.22 We found nothing in its published scope that pays for months of outpatient medicine.
How do I check my own policy?
Read the full policy wording. Search it for four words, then ask your insurer in writing before you count on any cover.
- Find the wording. Your policy schedule names the product and its UIN (unique identification number). Search the insurer's website for that product's policy wording.
- Search it for "outpatient", "OPD", "Excl06" and "obesity". Note any yearly limit, and whether medicines or pharmacy are named.
- Check the add-ons listed on your schedule. Each has its own wording and limits.
- Ask in writing, quoting the medicine, the dose and the diagnosis on your prescription. Keep the reply.
- If a claim is refused, IRDAI says the insurer must quote "the specific terms and conditions" it relied on.19 You can complain to the insurer, then to the Insurance Ombudsman, whose award the insurer must follow within 30 days.19
For what a doctor's visit and tests involve, and where insurance fits in the full cost, see Guide 6. Our short answer on who can prescribe GLP‑1 medicines covers the prescription itself.
Questions people ask
Does insurance cover Ozempic for diabetes in India?
Usually not, because it's bought as an outpatient. Star Health's Diabetes Safe pays outpatient costs only at network facilities, up to ₹1,000–5,500 a year per person on Plan A and from ₹500 on Plan B. Even ₹5,500 is less than a month at Ozempic's starting dose.4,5
Is Mounjaro covered by health insurance in India?
Not by most base policies, which exclude outpatient treatment. Under the government's CGHS scheme, it has been allowed under strict rules since 24 July 2026.1,7
Does insurance cover Wegovy for weight loss in India?
Rarely. IRDAI data reported in March 2026 shows obesity-related therapies are largely excluded from retail health policies.12
Does health insurance cover bariatric surgery in India?
It can. Policies using the standard Excl06 wording don't exclude surgery that meets every condition.3 They include a doctor's advice, age 18 or over, and a BMI of 40, or 35 with listed conditions. Sublimits can still apply.3,15
Can my employer's policy cover GLP-1 medicines?
It can, if your employer bought outpatient cover that includes pharmacy. Ask HR for the wording and the yearly limit.6
How we researched this
On 5 October 2026 we opened IRDAI's 2019 exclusion guidelines, its 2020 master circular on standard products and its 2024 health master circular. We also opened 7 policy wordings from 5 insurers. We quote them as text. We name insurers only to quote their wording, and we link no page that sells a policy.
Star Health's website blocked us, so we used the 2021 wording filed with IRDAI. We found no IRDAI statement on GLP‑1 medicines, and no public data on employer policies. Clinic websites claim some named employers pay for Ozempic, but give no source, so we left that out.
Before you move on
- Most base policies exclude outpatient treatment, which is how GLP‑1 medicines are used.
- The standard obesity exclusion (Excl06) that IRDAI set in 2019 is about surgery, with a bar of BMI 40, or 35 with listed conditions.
- OPD and diabetes add-ons have yearly limits, and some exclude medicines entirely.
- Ask your insurer or HR in writing before you count on cover.
More from the India blog
What changed for Ozempic when semaglutide's patent expired in India?
What does a year on Ozempic, Mounjaro or Wegovy cost in India, all in?
Bariatric surgery vs GLP-1 medicines: results, risks and costs in India
The monthly India update
An independent guide to GLP‑1 medicines. We don't sell medicines or insurance, take drug-company money or earn clinic commissions. Once a month: new brands, price changes, approvals and recalls. How we write
Sources
- HDFC ERGO General Insurance. my: Optima Secure, policy wording, UIN HDFHLIP26058V082526. Post-hospitalisation (B-1.6, definition 37), exclusions Excl06 and "Treatment taken on outpatient basis". Quoted as text, not a recommendation. PDF
- HDFC ERGO General Insurance. Energy (diabetes and hypertension plan), policy wording and customer information sheet, UIN HDFHLIP26048V052526. Preamble, HbA1c Checkup Benefit, waiting-period note, exclusion "Treatment taken on Outpatient basis". Quoted as text, not a recommendation. PDF
- IRDAI. Guidelines on Standardization of Exclusions in Health Insurance Contracts, Ref IRDAI/HLT/REG/CIR/177/09/2019, 27 September 2019. Para 3.5, para 5 and Chapter III F (Excl06). Consolidated into the 2020 master circular (source 23), which the 2024 master circular superseded (source 16). PDF
- Star Health and Allied Insurance. Diabetes Safe Insurance Policy, policy wording, UIN SHAHLIP22029V072122, POL/DIA/V.12/2021 (copy on IRDAI's website), Section 3 Outpatient Expenses and limits table, page 4. Quoted as text, not a recommendation. PDF
- Business Standard. As generics wave builds up, Novo Nordisk slashes Ozempic, Wegovy prices. 31 March 2026. Link
- Universal Sompo General Insurance. Group Health Insurance Policy, policy wording, UIN UNIHLGP26043V062526. Extensions 9.4 and 9.10, specific exclusion E.2.1. Quoted as text, not a recommendation. PDF
- Ministry of Health and Family Welfare (EHS Section). Office Memorandum No. 1-360/18-19/CGHS/MSD (2740767/P)-Part (1611)/EHS(8354138), 24 July 2026: Guidelines for prescription of Injectable GLP-1 Receptor Agonists under CGHS and CS(MA) Rules, 1944, with Annexure-I. PDF (copy hosted by GConnect)
- PIB Research (Government of India). GLP-1 drugs: use, risks, and regulation. 1 April 2026. Key takeaways and "Regulation of GLP-1 drugs". PDF
- CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 100th meeting, 20–21 April 2023. Item 1, tirzepatide (Eli Lilly). PDF · archived copy
- CDSCO. Recommendations of the Subject Expert Committee (Endocrinology & Metabolism), 3rd/24 meeting, 13–14 February 2024. Items 3–4, semaglutide (Novo Nordisk). PDF · archived copy
- Alkem Laboratories. Press release: Alkem launches semaglutide injection in India (pen of four doses from ₹1,800). 21 March 2026. PDF
- BusinessToday (Neetu Chandra Sharma). Novo further cuts semaglutide prices as generics enter India. 31 March 2026. Link
- BusinessToday (Neetu Chandra Sharma). Why 2026 could be the turning point for India's obesity drug market. 31 December 2025. Link
- Niva Bupa Health Insurance. ReAssure 2.0, policy wording, UIN NBHHLIP27054V032627. Exclusion 5.1.6 (Excl06). Quoted as text, not a recommendation. PDF
- SBI General Insurance. Super Health Insurance, policy wording, UIN SBIHLIP24141V022324. Definition 22 (obesity), C.13 Bariatric Surgery Cover, Excl06. Quoted as text, not a recommendation. PDF
- IRDAI. Annexures to the Master Circular on Health Insurance Business, 29 May 2024. Annexure-6, Sl. 1: the 2020 Master Circular on Standardization of Health Insurance Products is superseded. PDF
- Misra A, et al. Consensus statement for diagnosis of obesity, abdominal obesity and the metabolic syndrome for Asian Indians and recommendations for physical activity, medical and surgical management. J Assoc Physicians India 2009;57:163-70. PMID 19582986. PubMed
- HDFC ERGO General Insurance. Optima Wellbeing (Add-on), policy wording, UIN as printed HDFHLIA2762V022627. General conditions 9 and 15, benefits 1–6. Quoted as text, not a recommendation. PDF
- IRDAI. Master Circular on Health Insurance Business (IRDAI (Insurance Products) Regulations 2024 – Health Insurance), Ref IRDAI/HLT/CIR/PRO/84/5/2024, 29 May 2024. Chapter I para 1 (OPD products and the note), para 4(b)(iv) (customer information sheet), paras 17(b), 19 and 20, Chapter II D.I.1 (product approval by the Product Management Committee). IRDAI document page
- Kasama K, et al. IFSO-APC consensus statements 2011. Obes Surg 2012;22:677-84. doi:10.1007/s11695-012-0610-7. PMID 22367008. PubMed
- Bhasker AG, et al. OSSI (Obesity and Metabolic Surgery Society of India) guidelines for patient and procedure selection for bariatric and metabolic surgery. Obes Surg 2020;30:2362-8. doi:10.1007/s11695-020-04497-1. PMID 32125645. PubMed
- Press Information Bureau. Transforming Healthcare: Six Years of Ayushman Bharat PM-JAY. 23 September 2024. Link
- IRDAI. Master Circular on Standardization of Health Insurance Products, Ref IRDAI/HLT/REG/CIR/193/07/2020, 22 July 2020. List of consolidated guidelines (item 9, the 2019 exclusions guidelines) and Section 2, Chapter III (standard wordings "in verbatim"; F, Excl06). Superseded 29 May 2024. PDF
- Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information, revised May 2026, Dosage and administration ("Administer once weekly"). US label, not the Indian one. PDF
- Eli Lilly. Mounjaro (tirzepatide) injection, US prescribing information, revised August 2026, Dosage and administration ("injected subcutaneously once weekly"). US label, not the Indian one. PDF
- Reuters. Novo Nordisk cuts Wegovy price by up to 37% in India. 11 November 2025 (2.4 mg: 16,400 rupees a month). Link
Last checked 5 Oct 2026 · Next review due 5 Apr 2027 · Report an error
How this post was made. Written by the GLP Guidebook team from the sources above. It's general information, not medical, financial or insurance advice. Talk to a qualified doctor before starting, stopping or changing any medicine. How we write